Novartis has been in the news for various reasons. Many recognize it as a top growth and momentum stock for the long term, based on its strong portfolio and innovative pipeline.
PTC Therapeutics saw a significant stock increase following a licensing agreement with Novartis. Schrödinger, too, entered into a collaboration pact with the company, in a deal worth up to $2.5 billion.
Novartis also licensed PTCT's Huntington's Disease Drug for a staggering $2.9 billion, which gave PTC's stock a boost. However, it was not all positive as
HSBC downgraded Novartis, and certain investment management firms reduced their holdings in the company. The pharmaceutical giant recently announced positive topline results from a Phase 3 study, and made waves in the market by increasing its fiscal outlook for 2024. Nonetheless, the company's stocks plunged in the short term, even though it landed major deals and collaborations. Despite this, the company is seen by many analysts as undervalued. Plus,
Novartis finds strong sales from key drugs, raises outlook for 2024, and shows promising signs of continued growth and profitability.
Novartis Stocks News Analytics from Thu, 25 Apr 2024 07:00:00 GMT to Sat, 07 Dec 2024 08:29:28 GMT -
Rating 5
- Innovation 8
- Information 7
- Rumor -5
